A Single Ascending Dose and Relative Bioavailability Study of LY2584702 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2017
At a glance
- Drugs LY 2584702 (Primary)
- Indications Solid tumours
- Focus Biomarker; Pharmacokinetics
- Sponsors Eli Lilly
- 26 Nov 2017 Results published in the Journal of Clinical Pharmacology
- 11 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jul 2011 Planned End Date changed from 1 Aug 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.